Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini

Blood (2018) 132 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2018-99-116864

Published: 2018

Journal Articles

Correlation of Somatic Mutations and Clinical Characteristics at Presentation in Patients with Essential Thrombocytemia

Aleksandar Eftimov, Mr Pharm, Irina Panovska-Stavridis, MD, Marija Popova-Simjanovska, MD, Martin Ivanovski, MD, Aleksandar Stojanovic, MDPhD, Lidija Cevreska, MDPhD, Nadica Geshkovska Matevska, Mr.Sci, Aleksandar J Dimovski, MDPhD

Blood (2014) 124 (21): 5582.

https://doi.org/10.1182/blood.V124.21.5582.5582

Published: 2014

Journal Articles

Familiar JAK2 G571S Variant Not Linked with Essential Trombocythemia

Irina Panovska-Stavridis, MD PhD, Aleksandar Eftimov, Mr.Sci, Aleksandra Pivkova-Veljanovska, MDPhD, Martin Ivanovski, MD, Lidija Cevreska, MDPhD, Aleksandar J Dimovski, MDPhD

Blood (2014) 124 (21): 5585.

https://doi.org/10.1182/blood.V124.21.5585.5585

Published: 2014

Journal Articles

The PTPN22 R620W Polymorphism Is Not Associated With Clinical and Molecular Correlates Of Chronic Lymphocytic Leukemia (CLL) In Patients Originating From a Region With Low Prevalence Of The Autoimmunity Risk Variant

Irina Panovska-Stavridis, Sanja Trajkova, Aleksandar Eftimov, Martin Ivanovski, Dusko Dukovski, MD, Popova-Simjanovska Marija, Staninova Marija, Lidija Cevreska, Aleksandar Dimovski

Blood (2013) 122 (21): 5277.

https://doi.org/10.1182/blood.V122.21.5277.5277

Published: 2013

Journal Articles

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, MD, Lidija Cevreska, Auro del Giglio, MD, Anna Vanazzi, Daniele Laszlo, Johann Raats, Daniel Rauch, Daniel A. Vorobiof, Andreas Lohri, MD, Emanuele Zucca, MD, Christine Biaggi Rudolf, Stephanie Rondeau, Corinne Rusterholz, Michele Ghielmini, MD

Blood (2013) 122 (21): 508.

https://doi.org/10.1182/blood.V122.21.508.508

Published: 2013

Journal Articles

Frequency and Clinical Correlates of JAK2 46/1 Haplotype in Comparison with JAK2V617F Variant in Myeloproliferative Neoplasms: Single Center Experience

Irina Panovska, MD, PhD, Nadica Matevska, Mr.Sci, Martin Ivanovski, MD, Sanja Trajkova, MD, Mr.Sci, Dusko Dukovski, MD, Lidija Cevreska, MD, PhD, Aleksandar Dimovski, MD, PhD

Blood (2011) 118 (21): 5173.

https://doi.org/10.1182/blood.V118.21.5173.5173

Published: 2011

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Simona Bassi, Felicitas Hitz, Walter Mingrone, Thomas Pabst, Lidija Cevreska, MD, PhD, Auro del Giglio, MD, Daniel A. Vorobiof, Mathew Simcock, Michele Ghielmini, MD

Blood (2010) 116 (21): 1802.

https://doi.org/10.1182/blood.V116.21.1802.1802

Published: 2010

Journal Articles

Treatment of CD 20+ Hodgkin Lymphoma (Lymphocyte Predominant) with Monoclonal Antibody Rituximab after First-Line Treatment Is Effective and Might Improve the Outcome

Sonja Genadieva-Stavrik, PhD, MD, Alexandra Pivkova, Ljube Ivkovski, Lidija Cevreska

Blood (2008) 112 (11): 5007.

https://doi.org/10.1182/blood.V112.11.5007.5007

Published: 2008

Journal Articles

A Case Report of Aggressive Adult Neuroblastoma Mimicking Acute Leukemia with Fulminant Course and Fatal Outcome

Irina Panovska, MD, Martin Ivanovski, Sanja Trajkova, Aleksandra Pivkova, Sonja Genadieva-Stavric, Liljana Hadzi-Pecova, Arif Latifi, Dejan Trajkov, Mirko Spiroski, Lidija Cevreska

Blood (2008) 112 (11): 4893.

https://doi.org/10.1182/blood.V112.11.4893.4893

Published: 2008

Journal Articles

Identification of Homozygous JAK2V617F Mutation in Unfractioned Blood Samples in a Substantial Proportion of Myeloproliferative Disorders: Long Term Follow-Up Study.

Irina Panovska, Nadica Matevska, Martin Ivanovski, Sanja Trajkova, Aleksandar Stojanovik, Aleksandar Dimovski, Lidija Cevreska

Blood (2007) 110 (11): 4644.

https://doi.org/10.1182/blood.V110.11.4644.4644

Published: 2007

Journal Articles

Initial Treatment of CD20+ Lymphocyte Predominant Hodgkin Lymphoma with Chemotherapy and the Monoclonal Antibody Rituximab-Mabthera Is Effective and Well Tolerated - Case Report.

Sonja G. Genadieva-Stavrik, PhD, Lubomir Ivkovski, PhD, Aleksandra Pivkova, MD, Lidija Cevreska, PhD

Blood (2006) 108 (11): 4696.

https://doi.org/10.1182/blood.V108.11.4696.4696

Published: 2006

Journal Articles

Chronic Lymphocytic Leukemia Patients with a V1-69 Gene Rearrangement Do Not Have Inferior Survival with Respect to Patients That Express Other Unmutated V H Genes.

Irina Panovska, MD, MSc, Martin Ivanovski, MD, Marica Pavkovic, MD, Nikola Siljanovski, MD, PhD, Liljana Hadzi-Pecova, MD, PhD, Aleksandar Stojanovic, MD, PhD, Lidija Cevreska, MD, PhD, Dimitar G. Efremov, MD, PhD

Blood (2005) 106 (11): 1193.

https://doi.org/10.1182/blood.V106.11.1193.1193

Published: 2005

NARROW

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Correlation of Somatic Mutations and Clinical Characteristics at Presentation in Patients with Essential Thrombocytemia

Familiar JAK2 G571S Variant Not Linked with Essential Trombocythemia

The PTPN22 R620W Polymorphism Is Not Associated With Clinical and Molecular Correlates Of Chronic Lymphocytic Leukemia (CLL) In Patients Originating From a Region With Low Prevalence Of The Autoimmunity Risk Variant

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Frequency and Clinical Correlates of JAK2 46/1 Haplotype in Comparison with JAK2V617F Variant in Myeloproliferative Neoplasms: Single Center Experience

Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

Treatment of CD 20+ Hodgkin Lymphoma (Lymphocyte Predominant) with Monoclonal Antibody Rituximab after First-Line Treatment Is Effective and Might Improve the Outcome

A Case Report of Aggressive Adult Neuroblastoma Mimicking Acute Leukemia with Fulminant Course and Fatal Outcome

Identification of Homozygous JAK2V617F Mutation in Unfractioned Blood Samples in a Substantial Proportion of Myeloproliferative Disorders: Long Term Follow-Up Study.

Initial Treatment of CD20+ Lymphocyte Predominant Hodgkin Lymphoma with Chemotherapy and the Monoclonal Antibody Rituximab-Mabthera Is Effective and Well Tolerated - Case Report.

Chronic Lymphocytic Leukemia Patients with a V1-69 Gene Rearrangement Do Not Have Inferior Survival with Respect to Patients That Express Other Unmutated V H Genes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only